Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00227318 · ClinicalTrials.gov registry record · Phase 3
TROPHY - Candesartan Cilexetil Long-term Hypertension Prevention Trial
A Phase 3 study of Hypertension, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,000
- Enrollment target
- 20
- Study locations
NCT00227318: Completed Phase 3 study of Hypertension, sponsored by AstraZeneca.
NCT00227318 is a Phase 3 study of Hypertension that has completed, run by AstraZeneca. The registered enrollment target is 1,000 participants, below the 3,505-participant average among 470 other Hypertension trials with a reported enrollment target (71% lower). The trial reports 20 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00227318, a Phase 3 study of Hypertension, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,000 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to determine the effectiveness of candesartan cilexetil in preventing hypertension in people with high normal blood pressure. Patients will be randomized to either Candesartan or placebo for an initial 2-year period followed by a second 2-year period of placebo for all patients.
Conditions Studied
Interventions
- DRUG ATACAND
Study Locations (20)
California
- Research Site - Long Beach
- Research Site - Redondo Beach
- Research Site - Santa Ana
- Research Site - Tustin
Florida
- Research Site - Bay Pines
- Research Site - Gainsville
- Research Site - Ocala
Missouri
- Research Site - Florissant
- Research Site - Kansas City
- Research Site - St Louis
Michigan
- Research Site - Chelsea
- Research Site - Detroit
Alabama
- Research Site - Mobile
Delaware
- Research Site - Wilmington
District of Columbia
- Research Site - Washington D.C.
Illinois
- Research Site - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,000 participants |
| Start Date | 1998-07 |
| Est. Completion | 2005-10 |
| Phase | Phase 3 |
What the finished NCT00227318 record still lists
NCT00227318 is an interventional study that assigns participants to a tested intervention. Its 1,000 participants enrollment target places it among the larger protocols in the corpus, below the 3,505-participant average among 470 other Hypertension trials with a reported enrollment target (71% lower).
The record links to 1 condition, with Hypertension appearing as the primary indexed condition, and to 1 intervention - of which ATACAND is the first listed.
NCT00227318 names 20 study sites across 12 states, led by California, Florida, Missouri.
Frequently Asked Questions
What is clinical trial NCT00227318 about?
NCT00227318 is a clinical study titled "TROPHY - Candesartan Cilexetil Long-term Hypertension Prevention Trial". The purpose of this study is to determine the effectiveness of candesartan cilexetil in preventing hypertension in people with high normal blood pressure. Patients will be randomized to either Candesartan or placebo for an initial 2-year period followed by a second 2-year period of placebo for all p...
What is the current status of trial NCT00227318?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,000 participants. The study started on 1998-07. Estimated completion is 2005-10.
What conditions does trial NCT00227318 study?
This clinical trial studies the following conditions: Hypertension.
What interventions are being tested in trial NCT00227318?
The interventions under investigation include: ATACAND (DRUG).
Who is sponsoring clinical trial NCT00227318?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00227318 being conducted?
This trial has 20 study locations across Alabama, California, Delaware, District of Columbia, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hypertension
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00227318's enrollment target sits among peer trials
1,000 65th of 470 higher than 396 of 470 other Hypertension trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hypertension trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease
RECRUITING · Phase 3
-
Renal Artery Denervation Assessment Without Antihypertensive Medication Regimen (RADAR)
RECRUITING · Phase 3
-
A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL1
RECRUITING · Phase 3
-
Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease
RECRUITING · Phase 3
-
A Master Protocol for Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight: (ATTAIN-Hypertension Screening)
RECRUITING · Phase 3
-
A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL2
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00018044 · 1,000 participants
Study of Mycobacterial Infections
- NCT01036581 · 1,000 participants · NA
Advanced Functional and Structural MRI Techniques for Neuropharmacological Imaging
- NCT01192048 · 1,000 participants
Genetics of Congenital Heart Disease
- NCT01553214 · 1,000 participants · Phase 4
Improving White Blood Cell Collection From Healthy Donors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia